Bridgeline Digital (BLIN) Q2 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Thomas Windhausen - CFO & TreasurerAri Kahn - President & CEOCasey Ryan - Director - Institutional Research Operator Please note this conference is being recorded. I will now turn the conference over to your host, Tom CFO. The floor is yours. Thomas Windhausen Excellent. Thank you. Good afternoon, everyone. Thanks for joining us today. My name is Tom Windhauser, and I'm the chief financial officer of Bridgeline Dig ...

NRx Pharmaceuticals (NRXP) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Matthew Duffy - Chief Business Officer & Co-CEO of Hope TherapeuticsJonathan Javitt - Founder, Chairman, Chief Scientist & Co-CEO of Hope TherapeuticsMichael Abrams - CFO Conference Call Participants Thomas Shrader - MD & Healthcare AnalystEdward Woo - Director of Research & Senior Analyst Operator Good afternoon, ladies and gentlemen, and welcome to the NRx Pharmaceuticals First Quarter twenty twenty five Earning ...

Financial Data and Key Metrics Changes - Revenue for Q1 2025 increased by 47% year-over-year to $7,900,000, exceeding guidance of $7,800,000, driven by balanced growth in the Vinia business [5][20] - Gross profit rose by 53% to $4,600,000, representing 58.5% of total revenue, up from 56.2% a year ago, primarily due to increased manufacturing scale and improved yield [20][21] - Net loss for Q1 2025 was $2,300,000, or $0.13 per share, compared to a net loss of $6,600,000, or $0.48 per share in the same quarter last year [21][22] Business Line Data and Key Metrics Changes - The Direct to Consumer Health and Wellness Products Division, led by Vinia, accounted for the majority of revenue, with total active subscribers exceeding 50,000 in the USA, and recurring subscribers making up 90% of revenue [6][13] - The Amazon channel represented 20% of the business, with improvements in customer conversion and repeat purchase rates [6] - The company launched new products, including a superfood tea lineup and plans for a hydration beverage, targeting significant market segments [9][12][60] Market Data and Key Metrics Changes - The company is expanding its reach into new consumer segments and channels, including international shipping and social media platforms like TikTok [42][43] - The market for non-GMO, plant-based compounds is growing, with increasing consumer awareness of health benefits related to blood flow and longevity [8][79] Company Strategy and Development Direction - The company aims to achieve adjusted EBITDA breakeven at $11,000,000 to $12,000,000 in quarterly revenue by the second half of 2025, focusing on balancing growth with profitability [17][18] - Strategic investments will be made in expanding the direct-to-consumer portfolio, enhancing R&D processes, and building AI-powered tools for CDMO services [18] - The company is targeting a 20% adjusted EBITDA margin for its direct-to-consumer division and higher margins in the CDMO segment [18] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to execute its growth strategy and deliver life-changing compounds, highlighting the synergy between the direct-to-consumer and CDMO divisions [23][70] - The company is optimistic about the increasing interest from pharmaceutical companies in its botanical synthesis technology, which offers consistent and economically viable compounds [70][71] Other Important Information - The company raised $3,900,000 in debt financing during the quarter, increasing cash and cash equivalents to $3,400,000 [22] - The company is preparing to launch the olivoboscoside cell product in 2026, targeting significant market opportunities in liver health and cholesterol management [13][79] Q&A Session Summary Question: Can you provide details on the Phase two portion of the CDMO contract? - Management explained that Phase two involves moving from solid media to liquid media for cell conditioning, with an expected timeline of six to nine months [27][28] Question: How long will it take to narrow down targets with Tate and Lyle? - Management indicated that significant work is underway, with a comprehensive update expected by the end of the year [30] Question: Should we expect continued gross margin expansion as revenue grows? - Management affirmed the intention to drive continued gross profit margin improvement alongside revenue growth [31][32] Question: How many products contributed to revenue in Q1, and how many are expected by year-end? - Management noted that three product lines contributed to Q1 revenue, with expectations to increase to four by Q2 and five by Q3 or Q4 [36][38] Question: Will marketing costs drop due to increased ad inventory? - Management highlighted efforts to reduce marketing costs as a percentage of revenue while exploring new channels for customer acquisition [39][44] Question: Does the second quarter guidance include contributions from the CDMO business? - Management confirmed that the guidance includes revenue recognition from existing CDMO projects and potential new catalysts [45][46] Question: How many CDMO programs can be run concurrently? - Management stated that the current capacity allows for five to seven concurrent projects in stage one [49] Question: What is the long-term opportunity for the beauty product? - Management discussed a focused strategy on high-margin categories, including health and beauty, with plans for a launch in Q1 next year [60][61]

Omeros Corp (OMER) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jennifer Cook Williams - PrincipalGregory Demopulos - Founder, Chairman, CEO & PresidentDavid Borges - VP of Finance, Chief Accounting Officer & TreasurerSteve Brozak - President & Managing PartnerNadia Dac - CCO Operator Good afternoon, and welcome to today's earnings call for Omeros Corporation. At this time, all participants are in a listen only mode. After the company's remarks, we will conduct a question and answer s ...

Zomedica (ZOM) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Jason Westphal - Sr. Director - FP&A, Reporting and M&ALarry Heaton - CEO & DirectorMike Zuehlke - Vice President of Finance & Corporate Controller Operator call is being recorded on Thursday, 05/15/2025. I would now like to turn the conference over to Jason Westfall, Senior Director, FP and A. Please go ahead. Jason Westphal Thank you, operator, and good afternoon, ladies and gentlemen. Welcome to Zometika's first quarter tw ...

Take-Two Interactive (TTWO) Q4 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Nicole Shevins - SVP of IR & Corporate CommunicationsStrauss Zelnick - Chairman and CEOKarl Slatoff - PresidentLainie Goldstein - CFODoug Creutz - Managing DirectorChristopher Schoell - Equity Research AssociateAndrew Marok - DirectorJames Heaney - SVP - Equity Research Conference Call Participants Eric Handler - MD & Senior Research AnalystColin Sebastian - Senior Research AnalystMatthew Cost - AnalystEric Sheri ...

P3 Health Partners (PIII) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Ryan Halsted - Managing DirectorAric Coffman - CEOLeif Pedersen - Chief Financial OfficerAmir Bacchus - Co-Founder and Chief Medical OfficerAaron Wukmir - Healthcare Equity Research AssociateJoshua Raskin - Partner - Managed Care & Providers Conference Call Participants Ryan Langston - Director & Senior Analyst - Healthcare Research Operator Good day, and welcome to the P3 Health Partners First Quarter twenty twent ...

Legacy Education (LGCY) Q3 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Nicole Joseph - SVP of MarketingLeeAnn Rohmann - Founder, CEO & Chair of the BoardBrandon Pope - CFOJeffrey Cohen - MD - Equity Research Conference Call Participants Mike Grondahl - Head of Equities, Director of Research & Senior Research Analyst Operator Good day, and welcome to the Legacy Education Third Quarter Fiscal twenty twenty five Earnings Conference Call. Today's call is being recorded and broadcast live. I ...

Beam Global (BEEM) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Lisa Potok - Chief Financial OfficerDesmond Wheatley - Chairman, Chief Executive Officer & PresidentNoel Parks - Managing Director - Energy Research Conference Call Participants Ryan Pfingst - Senior Research Analyst Operator Good day, and welcome to the Beam Global First Quarter twenty twenty five Operating Results Conference Call. All participants will be in a listen only mode. Please note this event is being recorded. ...

Gossamer Bio (GOSS) Q1 2025 Earnings Call May 15, 2025 04:30 PM ET Company Participants Bryan Giraudo - COO & CFOFaheem Hasnain - Co-Founder, CEO & ChairmanRichard Aranda - Chief Medical OfficerJoseph Schwartz - Senior Managing DirectorBob Smith - CCOCaryn Peterson - EVP - Regulatory AffairsPatrick Trucchio - Managing DirectorLaura Chico - Managing DirectorDaniel Krizay - VP - Biotech Equity Research Conference Call Participants Andreas Argyrides - Managing Director & Senior Analyst - BiotechnologyYasmeen R ...